AR087363A1 - Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres - Google Patents

Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres

Info

Publication number
AR087363A1
AR087363A1 ARP120102745A ARP120102745A AR087363A1 AR 087363 A1 AR087363 A1 AR 087363A1 AR P120102745 A ARP120102745 A AR P120102745A AR P120102745 A ARP120102745 A AR P120102745A AR 087363 A1 AR087363 A1 AR 087363A1
Authority
AR
Argentina
Prior art keywords
diagnosis
antibody
canceres
detection
cxcr4
Prior art date
Application number
ARP120102745A
Other languages
English (en)
Spanish (es)
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of AR087363A1 publication Critical patent/AR087363A1/es

Links

Classifications

    • G01N33/574—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ARP120102745A 2011-07-29 2012-07-27 Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres AR087363A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161513345P 2011-07-29 2011-07-29
EP11306000 2011-07-29
PCT/EP2012/064876 WO2013017562A1 (en) 2011-07-29 2012-07-30 Use of the antibody i-3859 for the detection and diagnosis of cancer

Publications (1)

Publication Number Publication Date
AR087363A1 true AR087363A1 (es) 2014-03-19

Family

ID=47628653

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102745A AR087363A1 (es) 2011-07-29 2012-07-27 Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres

Country Status (14)

Country Link
US (1) US20140170677A1 (enExample)
EP (1) EP2736926A1 (enExample)
JP (1) JP6138780B2 (enExample)
KR (1) KR20140047127A (enExample)
CN (1) CN103717620A (enExample)
AR (1) AR087363A1 (enExample)
AU (2) AU2012292116A1 (enExample)
BR (1) BR112014001979A2 (enExample)
CA (1) CA2842552A1 (enExample)
IL (1) IL230693A0 (enExample)
MX (1) MX2014001160A (enExample)
RU (1) RU2636032C2 (enExample)
WO (1) WO2013017562A1 (enExample)
ZA (1) ZA201400500B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108271422A (zh) * 2015-06-25 2018-07-10 株式会社国际电气通信基础技术研究所 基于器官间串扰系统的预测装置及预测程序
ES2837015T3 (es) * 2015-10-23 2021-06-29 Novartis Ag Sistema de derivación de proximidades espaciales entre células
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP4005598A1 (en) 2016-03-29 2022-06-01 Karydo Therapeutix, Inc. Screening method for candidate substances for active component to prevent or treat at least one disease selected from the group consisting of renal hypofunction, chronic kidney disease and kidney failure
CN109414504B (zh) 2016-03-29 2022-04-08 无限生物制药公司 药物组合物或食品组合物及评价活性成分体内效果的方法
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
CA3080821A1 (en) * 2017-11-07 2019-05-16 X4 Pharmaceuticals, Inc. Cancer biomarkers and methods of use thereof
WO2019200223A1 (en) * 2018-04-13 2019-10-17 X4 Pharmaceuticals, Inc. Cancer serum biomarkers and methods of use thereof
JP2023517956A (ja) 2020-03-10 2023-04-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 好中球減少症を処置する方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308996A1 (en) * 1998-03-30 2011-04-13 NorthWest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 and SDF-1 genes in tumourigenesis
DE60103052T2 (de) 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
CA2412436C (en) 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
WO2004096839A1 (en) * 2003-05-02 2004-11-11 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
CA2597717C (en) * 2005-02-18 2014-10-21 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
ES2625798T3 (es) * 2006-10-02 2017-07-20 E. R. Squibb & Sons, L.L.C. Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
EP2172485A1 (en) 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV

Also Published As

Publication number Publication date
CA2842552A1 (en) 2013-02-07
EP2736926A1 (en) 2014-06-04
WO2013017562A1 (en) 2013-02-07
ZA201400500B (en) 2014-11-26
US20140170677A1 (en) 2014-06-19
JP6138780B2 (ja) 2017-05-31
CN103717620A (zh) 2014-04-09
RU2014103054A (ru) 2015-09-10
JP2014523920A (ja) 2014-09-18
AU2012292116A1 (en) 2014-02-06
BR112014001979A2 (pt) 2017-02-21
IL230693A0 (en) 2014-03-31
AU2017204043A1 (en) 2017-07-06
MX2014001160A (es) 2014-07-14
RU2636032C2 (ru) 2017-11-17
KR20140047127A (ko) 2014-04-21

Similar Documents

Publication Publication Date Title
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
MX2020008976A (es) Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
GT201300276A (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
CL2016000883A1 (es) Compuestos macrocíclicos, inhibidores de antígeno prostático específico de membrana (psma); composición farmacéutica; complejo de metal; y su uso para preparar compuestos radiomarcados útiles para la formación de imágenes para diagnosticar y para el tratamiento de cáncer de próstata y/o metástasis de la misma.
MX2020001450A (es) Composiciones para reducir la inmunosupresion por celulas de tumor.
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
EA201491574A1 (ru) Применение car, основанных на icos, для усиления противоопухолевой активности и длительного сохранения car
MX2015006680A (es) Composiciones y metodos para diagnosticar tumores de tiroides.
MX365061B (es) Biomarcadores relacionados a la funcion renal y metodos para usar los mismos.
UY33647A (es) ?agentes de unión a cd33?.
MX356986B (es) Metodo para detectar aductos de nucleosomas.
MX2013005762A (es) Biomarcadores para la prediccion de la eficacia de una inmunoterapia contra el cancer.
BR112013010952A2 (pt) sistemas de rmn e métodos para a detecção rápida de analisados
MX370597B (es) Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer.
MX361058B (es) Método para detectar células tumorales circulantes 5t4-positivas y métodos de diagnóstico de cáncer 5t4-positivo en un sujeto mamífero.
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
BR112014002140A2 (pt) anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
BR112013005145A2 (pt) anticorpos anti-cxcl13 e métodos para seu uso
MX372753B (es) Uso de inhibidores de la telomerasa para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas.
BR112014001979A2 (pt) uso do anticorpo i-3859 para a detecção e diagnóstico de câncer
WO2012135340A3 (en) Compositions and methods for diagnosing cancer
EA201591742A1 (ru) Способ улучшения диагностики заболеваний с использованием измеряемых аналитов
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
MX2014006187A (es) Composiciones y metodos para el analisis de cancer de prostata.

Legal Events

Date Code Title Description
FB Suspension of granting procedure